Protokoll från årsstämma 2016-05-09 Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow us on: LinkedIn, [...]
Årsredovisning 2015 Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow us on: LinkedIn, Facebook and Twitter [...]
Clinical trial of Inofer: half of the patients already recruited WED, NOV 14, 2018 08:00 CET The tenth patient of twenty has now been recruited for the clinical study of the iron tablets Inofer, which Drugsson AB (subsidiary of Double Bond Pharmaceutical) has the rights [...]
DBP gets free Protocol Assistance from EMA for SI-053 TUE, NOV 06, 2018 08:13 CET Double Bond Pharmaceutical has submitted an application to EMA for scientific advice, known as Protocol Assistance, for SI-053. The assistance will be given during a pre-submission meeting, where DBP is [...]
Patent protecting Temodex and SI053 covering the Eurasian market has been granted MON, OCT 29, 2018 08:11 CET The institution of Physical and Chemical Problems´ (Minsk) patent application, which protects Temodex and SI053 has been granted by the Eurasian Patent Organization (EAPO). The patent approval [...]
Double Bond Pharmaceutical and Closter Pharma perform experience exchange MON, OCT 22, 2018 08:05 CET In week 44, i.e during 29/10 – 2/11, eight doctors from leading hospitals in Colombia will meet and exchange experiences with developers, manufacturers and users of Temodex in Belarus. During [...]
Clinical trial of Inofer has started FRI, OCT 05, 2018 08:45 CET The clinical study for the iron tablets Inofer, which Drugsson AB (subsidiary of Double Bond Pharmaceutical) has the rights for in Sweden, Norway, Denmark and Finland has now begun. A clinical trial of [...]
The preclinical development program of SI-053 is complete THU, OCT 04, 2018 08:43 CET The results of the two remaining preclinical studies are now available. The toxicological studies on SI053 and its formulation showed expected results. The study on the excipient was a long-term study [...]
Double Bond Pharmaceutical about to sell Temodex in Latin America FRI, SEP 28, 2018 08:09 CET Double Bond Pharmaceutical and CLOSTER PHARMA S.A.S (Colombia) have signed a distribution agreement for Temodex in Mexico, Brazil, Colombia, Peru, Ecuador and Costa Rica. The distribution will be carried [...]
The new issue of shares in FarmPharma via FundedByMe is closed WED, SEP 26, 2018 08:58 CET Today, 26 september the Board of FarmPharma AB, a wholly-owned subsidiary of Double Bond Pharmaceutical, has closed the new issue via FundedByMe. 83 investors participated in the rights [...]